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Abstract
Mantle cell lymphoma (MCL) is a specific type of aggressive B-cell non–Hodgkin lymphoma. We recently found
that IL-22RA1, one of the two subunits of the interleukin 22 (IL-22) receptor, is expressed in MCL cell lines but not
benign lymphocytes. In view of normal functions of IL-22 signaling, we hypothesized that the aberrant expression
of IL-22RA1 may contribute to the deregulation of various cell signaling pathways, thereby promoting cell growth
in MCL. In this study, we first demonstrated the expression of IL-22RA1 in all three MCL cell lines and eight frozen
tumors examined using reverse transcription–polymerase chain reaction and Western blot analysis. In support of
the concept that IL-22 signaling is biologically important in MCL, we found that MCL cells treated with recombinant
IL-22 had a significant increase in cell growth that was associated with STAT3 activation. To investigate the mech-
anism underlying the aberrant expression of IL-22RA1, we analyzed the gene promoter of IL-22RA1, and we found
multiple binding sites for NF-κB, a transcriptional factor strongly implicated in the pathogenesis of MCL. Pharma-
cologic inhibition of NF-κB resulted in a substantial reduction in the level of IL-22RA1 protein expression in MCL
cells. To conclude, IL-22RA is aberrantly expressed in MCL, and we have provided evidence that IL-22 signaling
contributes to the pathogenesis of MCL.
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Introduction
Mantle cell lymphoma (MCL) is a distinct clinicopathologic entity
recognized by the World Health Organization Classification Scheme
[1]. Development of resistance to conventional chemotherapeutic
agents is frequent, and the median survival is approximately 3 years
[2–5]. The genetic hallmark of this disease is the chromosomal ab-
normality, t(11;14)(q13;q32), which results in aberrant cyclin D1 ex-
pression in these neoplastic B cells [2]. Experimental results derived
from studies of the cyclin D1 transgenic mouse models support the
concept that enforced cyclin D1 expression in B cells is not sufficient
for lymphomagenesis [6]. Consistent with this view, an in vitro study
recently showed that the knockdown of cyclin D1 using small hair-
pin RNA has minimal effects on the survival of MCL cells [7]. Ac-
cumulating evidence has suggested that MCL tumors often carry a
relatively large number of biochemical abnormalities, including mul-
tiple defects in the regulation of the apoptotic pathway and cell cycle
progression [8–17]. These findings have highlighted the biological
complexity of MCL.
Interleukin 22 (IL-22) belongs to the family of IL-10–related pro-
teins, which includes IL-19, IL-20, IL-24/MDA-7, IL-26/AK155,
IL-28, and IL-29 [18–20]. IL-22 is normally produced by T lym-
phocytes and mucosal epithelial cells in various anatomic sites [21–
27]. It has been shown that IL-22 triggers intracellular signals by
binding to a heterodimeric receptor complex that is composed of
IL-22RA1 and IL-10R2 [28–31]. Although IL-10R2 is ubiquitously
expressed, IL-22RA1 is expressed in a relatively restricted pattern, be-
ing found at relatively high levels in the pancreas, small intestine,
colon, kidney, and liver [32–35]. Importantly, IL-22RA1 is not de-
tectable in immune cells including monocytes, resting or activated B/
T cells, natural killer cells, macrophages, and dendritic cells [36,37].
IL-22 is known to activate a number of signaling pathways including
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that of STAT3 and mitogen-activated protein kinase [29,38–41]. On
the basis of the current understanding of the biology of IL-22, it is
believed that IL-22 produced by T cells plays an important role in
enhancing innate immunity and tissue repair [26].
We have previously reported that the IL-22 signaling pathway
carry biological significance in the pathogenesis of ALK-positive ana-
plastic large cell lymphoma, a lymphoma of mature T-cell immuno-
phenotype [42]. We hypothesized that the IL-22 signaling may also
play a role in the pathogenesis of MCL by contributing to the consti-
tutive activation of STAT3 in MCL [17]. In this study, we first dem-
onstrated that the aberrant expression of IL-22RA1 is a consistent
phenomenon found in MCL cell lines and tumors. We then provided
evidence that the IL-22 signaling is biologically important in MCL.
Materials and Methods
Cell Culture and Chemicals
The characteristics of the three MCL cell lines, Jeko-1, Mino,
and SP53, have been previously described [43]. Briefly, all of these
three cell lines have the mature B-cell immunophenotype, carry the
t(11;14)(q13;q32) cytogenetic abnormality, and overexpress cyclin D1.
All three cell lines are negative for the Epstein-Barr virus nuclear
antigen. MCL cells were treated with 20 ng/ml of human recombi-
nant IL-22 protein (rIL-22; R&D Systems, Minneapolis, MN) for 0
and 30 minutes and harvested for Western blot analysis. To obtain
highly purified peripheral blood B cells from healthy donors, we first
collected peripheral blood mononuclear cells by centrifugation over
Ficoll-Hypaque. CD19-positive B cells were isolated by positive selec-
tion using specific monoclonal antibody–coated magnetic beads and
a preparative magnetic cell sorter (Miltenyi, Bergisch Gladbach,
Germany) in accordance with the manufacturer’s recommended pro-
tocol. The purity of the isolated B-cell population was analyzed by
flow cytometry (FACScan; Becton Dickinson, San Jose, CA) and con-
firmed to be greater than 98%. NF-κB activation inhibitor 6-amino-4-
(4-phenoxyphenylethylamino quinazoline (catalog no. EI-352) was
purchased from Enzo Life Sciences International (Farmingdale, NY)
and E -2-fluoro-4′-methoxystilbene (catalog no. 481412) was pur-
chased from EMD (Gibbstown, NJ).
Western Blot Analysis and Antibodies
Western blot analysis was performed using standard techniques.
Briefly, cells were lysed in a buffer containing 20 mM Tris-HCl,
pH 7.5, 5 mM EDTA, 40 μg/ml leupeptin, 1 μM pepstatin, and
Table 1. Primer Sequence.
Sense Primers Antisense Primers Product Size (bp)
IL-22 TTCTCTTGGCCCTCTTGGTA TTCTCCCCAATGAGACGAAC 169
IL-22RA1 TGCTGACCATCTTGACTGTG TCCCTCTCTCCGTACGTCTTAT 181
IL-22BP GGAACTCAGTCAACGCATGA TTGGCTTCTGGTGAGAGCTT 178
IL-10Rb TACCACCTCCCGAAAATGTC CAAATTCAGCCCTGACTCTCA 219
GAPDH AAGGTCATCCCTGAGCTGAA CCCTGTTGCTGTAGCCAAAT 316
Figure 1. The expression of IL-22RA1 in MCL cell lines and patient tumors. RT-PCR studies demonstrated the presence of IL-22RA1
messenger RNA (mRNA) in all three MCL cell lines and in the eight MCL patient samples (A). The HepG2 cell line was included as a
positive control for IL-22RA1, and normal B cells was included as a negative control. GAPDH was included as an internal control. West-
ern blot analysis confirmed the protein expression of IL-22RA1 in all three MCL cell lines and the eight MCL patient samples (B). HepG2
cells were used as a positive control for IL-22RA1, and normal human B cells were used as a negative control (B).
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1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride and centrifuged at
15,000g for 15 minutes at 4°C. The supernatant was removed, and
50 to 100 μg of protein was run on an SDS–polyacrylamide gel. Af-
ter the proteins were transferred to nitrocellulose membranes, the
membranes were blocked with 5% milk in TBS buffer (20 mM
Tris-HCl, pH 7.6, 150 mM NaCl) and then incubated with primary
antibodies overnight followed by 1 hour of incubation with horserad-
ish peroxidase–conjugated secondary antibody ( Jackson Immunore-
search Laboratories, Inc, West Grove, PA). Membranes were washed
in PBS with 0.05% Tween-20 for 30 minutes between steps. Proteins
were detected using the enhanced chemiluminescence detection kit
(Amersham Life Sciences, Arlington Heights, IL). Antibodies used were
anti-STAT3 (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA), anti-
pSTAT3 (1:500; Santa Cruz Biotechnology), anti-IL-22RA1 (1:1000;
Sigma-Aldrich, Oakville, Ontario, Canada), and anti–β-actin (1:3000;
Sigma-Aldrich).
Immunofluorescence Staining and Confocal Microscopy
Immunofluorescence was performed using standard techniques.
Briefly, cells grown on coverslip in a six-well plate were fixed with
4% paraformaldehyde in PBS. Cells were rinsed three times with
1× PBS, incubated with 30 μl of anti–IL-22RA1 (1:50; Sigma-
Aldrich) antibody overnight followed by rinsing three times with
1× PBS. After incubating with 200 μl of Alexa Fluor 488 second-
ary antibody (1:250; Invitrogen, Burlington, Ontario, Canada) for
1 hour at room temperature, cells were rinsed with PBS, and the pro-
cedure was completed with a mounting medium (Dako, Mississauga,
Ontario, Canada) added to the slides. Cells were visualized with a
Figure 2. Flow cytometric detection of IL-22RA1 in MCL cell lines. (A) Three MCL cell lines were subjected to flow cytometry analysis
with a specific anti–IL-22RA1 antibody. All three cell lines were shown to express IL-22RA1. The black lines correspond to the isotype
control and the red lines illustrate the IL-22RA1 reactivity. (B) Flow cytometry analysis was also performed using the peripheral blood
mononuclear cells from a healthy donor. The black lines correspond to the isotype control, and the green lines illustrate IL-22RA1 re-
activity. Normal peripheral blood mononuclear cells (total) as well as specific subsets of cells (including lymphocytes, monocytes, and
granulocytes) were negative for IL-22RA1. The positive control (HepG2 cell line) showed a strong signal. The gating strategy is illustrated
in the right lower panel.
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Zeiss LSM 510 (Carl Zeiss, Toronto, Canada) confocal microscope at
the Core Cell Imaging Facility, Cross Cancer institute.
Flow Cytometric Detection of IL-22RA1 MCL Cell Lines
MCL cells were fixed in the CytoFix Buffer from Becton Dickinson
Biosciences (Franklin Lakes, NJ) washed in cold PBS, centrifuged, and
resuspended in the FACS staining buffer purchased from Becton
Dickinson. Cells were incubated with primary antibodies for 60 minutes
at 4°C in the dark and washed twice using cold buffer between incuba-
tions. The following antibodies were used: unconjugated mouse IgG1 as
the isotype control (10 μg/ml; Santa Cruz Biotechnology), unconjugated
mouse anti–human IL-22RA1 (IgG1, 10 μg/ml; R&D Systems), and
phycoerythrin-conjugated rat anti–mouse antibody (IgG1, 5 μg/ml;
Becton Dickinson). Flow cytometry was performed using the FACScan
(Becton Dickinson, Toronto, Canada), and data were analyzed using the
accompanying CELLQuest software as per manufacturer’s guidelines.
Reverse Transcription–Polymerase Chain Reaction
Total cellular RNA was extracted from 1 × 106 cells from Mino,
SP53, Jeko-1, purified human B cells, and HepG2 cell lines using the
TRIzol extraction method (Invitrogen). Reverse transcription (RT) was
performed using 500 ng of total RNA in a first-strand complementary
DNA synthesis reaction with SuperScript Reverse Transcriptase as
recommended by the manufacturer (Invitrogen). Primer pairs were de-
signed to detect IL-22, IL-22RA1, and IL-10R2. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as an internal control.
Polymerase chain reaction (PCR) was performed by adding 5 μl of RT
product into a 25-μl volume reaction containing 1× buffer, 200 μM of
each dNTPs, oligonucleotide primer, and 0.2 U of AmpliTaq polymer-
ase. The primer sequences and PCR cycles are shown in Table 1. For
DNA amplification, complementary DNA was denatured at 94°C for
1 minute, subjected to primer annealing at 60°C for 1 minute, and then
subjected to DNA extension at 72°C for 1minute for 35 cycles in a ther-
mal cycler (Applied Biosystems, Foster City, CA). Amplified products
were analyzed by DNA gel electrophoresis in 1% agarose and visualized
by the Alpha Imager 3400 (Alpha Innotech, San Leandro, CA).
Cell Growth Assay
For the MTS assay (Promega, Madison, WI), 5000 cells were seeded
in 96-well culture plates and treated daily with recombinant IL-22 up to
6 days. Cell proliferation was then measured colorimetrically at 450 nm
using a Microplate reader (BioRad, Hercules, CA), and absorbance
values were normalized using the Microplate Manager 5.2.1 (BioRad).
MCL Tumors and Immunohistochemistry
All MCL primary tumors were diagnosed at the Cross Cancer In-
stitute, and the diagnostic criteria were based on those described in
the World Health Organization Classification Scheme [1]. All cases
were confirmed to express cyclin D1 by immunohistochemistry. The
use of these tissues has been approved by our institutional ethics com-
mittee. Immunohistochemical staining was performed using standard
techniques. Briefly, formalin-fixed, paraffin-embedded tissue sections
of 4-μm thickness were deparaffinized and hydrated. Heat-induced
epitope retrieval was performed using Tris buffer (pH 9.9; Dako)
and a rapid microwave histoprocessor (RHS; Milestone, Bergamo,
Italy). After incubating at 100°C for 10 minutes, slides were washed
in running tap water for 5 minutes, and endogenous peroxidase was
blocked using 10% H2O2 and methanol followed by washing in run-
ning tap water. Tissue sections were then incubated with anti–IL-
22RA1 (1:500; Capralogics, Hardwick, MA) overnight in a humidified
chamber at 4°C. After three washes with PBS, tissue sections were
incubated with anti–rabbit IgG (EnVision, Dako) for 30 minutes
at room temperature. The tissue sections were incubated with 3,3′-
diaminobenzidine/H2O2 (Dako) for color development, using hema-
toxylin as a counterstain. For IL-22RA1, liver tissues were used as a
positive control, and benign tonsils were used as a negative control.
Statistical Analysis
All the experiments were performed in triplicate. Student’s t test
was used. P < .05 was considered to be statistically significant.
Results
Expression and Subcellular Localization of IL-22RA1 in
MCL Cell Lines and Tumors
We first demonstrated the expression of IL-22RA1 using RT-PCR.
RNA extracted from eight MCL frozen tumors and three cell lines
were used, and the results are illustrated in Figure 1A. Amplifiable
IL-22RA1 signal was detectable in all eight tumors (labeled MCL-
P1 to MCL-P8) and in all three cell lines examined (Mino, SP53,
Figure 3. Subcellular localization of IL-22RA1 in MCL cell lines. Immunofluorescence staining using antibodies directed against IL-22RA1
(lower panel) or control IgG (upper panel) was assessed by confocal microscopy. The results revealed a membranous staining pattern
for IL-22RA1 in the three MCL cell lines, Mino, SP53, and Jeko-1.
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and Jeko-1). HepG2 (a hepatocarcinoma cell line) and benign B cells
served as the positive and negative controls, respectively. The PCR
products were sequenced and confirmed to be full-length IL-22RA1
(not shown).
We then detected the protein expression of IL-22RA1 in MCL
cells using Western blot. As shown in Figure 1B, IL-22RA1 protein
was detectable in the same eight MCL tumors and three MCL cell
lines used for Figure 1A. HepG2 and benign peripheral blood B cells
served as the positive and negative controls, respectively. As shown in
Figure 2A, the expression of IL-22RA1 on the surface of MCL cells
was detectable by flow cytometry; specifically, all three MCL cell
lines showed a significant shift to the right compared with the isotype
controls. Triplicate experiments were performed, and results from a
representative experiment are shown. In contrast, peripheral blood
mononuclear cells, as well as the gated lymphocytes, monocytes,
and granulocytes, revealed no appreciable shift compared with the
isotype controls (Figure 2B). HepG2 cells served as the positive con-
trols in these experiments.
We then assessed the subcellular localization of IL-22RA1 using im-
munofluorescence staining and confocal microscopy. As shown in Fig-
ure 3, IL-22RA1 was found localized to the cell membrane of MCL
cells. The isotype control revealed no detectable signal. Using immu-
nohistochemistry applied to paraffin-embedded MCL tumors (n =
10), we were able to demonstrate membranous staining of IL-
22RA1 in all cases (Figure 4, B–D). In contrast, reactive tonsilar lym-
phoid tissues including the mantle zone were negative (Figure 4A).
Expression of IL-22RB in MCL Cell Lines and Tumors
Using RT-PCR, we then assessed the expression of IL-10RB, the
other subunit of the IL-22 receptor, in MCL cell lines and patient
samples. As shown in Figure 5, amplifiable IL-10RB signals were
Figure 4. Detection of IL-22RA1 by immunohistochemistry in MCL tumors. Immunohistochemical staining of IL-22RA1 using paraffin-
embedded tissue sections. (A) Benign lymphoid tissues in reactive tonsil showed no reactivity in the mantle zones and a faint back-
ground staining in the germinal centers (magnification, ×200). (B) Neoplastic lymphoid nodules in a case of MCL showed definitive
reactivity with anti–IL-22RA1 (magnification, ×40). (C and D) The neoplastic nodules in a case of MCL showed reactivity with anti–IL-
22RA1, whereas the benign infiltrating lymphocytes adjacent to the neoplastic nodules (as highlighted by the black arrows) were neg-
ative (magnifications, ×200 and ×400, respectively).
Figure 5. IL-10RB expression in MCL cell lines and tumors. RT-PCR to detect the expression of IL-10RB was performed using a specific
set of primer (Table 1). Amplifiable IL-10RB signals were detectable in all three MCL cell lines (A) and five MCL tumor samples (B).
Translational Oncology Vol. 4, No. 1, 2011 IL22 in Mantle Cell Lymphoma Gelebart et al. 13
Figure 6. IL-22 expression in MCL. RT-PCR studies demonstrated the presence of IL-22 mRNA in MCL tumors. HepG2 cells were in-
cluded as a negative control and GAPDH was included as an internal control. MCL cell lines are negative for IL-22 (A). In eight MCL
tumor samples, five are positive for IL-22 mRNA (B). In contrast, HepG2 cells and normal B cells were negative.
Figure 7. Addition of rIL-22 increased the number of viable cells. Treatment of three MCL cell lines with rIL-22 (20 ng/ml daily) induced a
significant increase in the number of viable cells, as revealed by the Trypan blue exclusion assay (A, D, and G). Four independent ex-
periments were performed. Error bars, SDs with the indicated P value. Using the MTS assay, we found that the rIL-22 treatment of MCL
cells induced a significant increase in the number of viable cells (B, E, and H). Six independent experiments were performed. Western
blot studies revealed that treatment with rIL-22 (0, 5, 10, 20, 40, and 80 ng/ml) for 30 minutes increased the level of pSTAT3 in all three
MCL cell lines (C, F, and I).
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Figure 7. (continued).
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Figure 8. IL-22RA1 expression is dependent on NF-κB activation. MCL Mino cells were treated with two potent NF-κB inhibitors, includ-
ing 6-amino-4-(phenoxyphenylethylamino)quinazoline (A and C) and E -2-fluoro-4′-methoxystilbene (B and D). Inhibition of NF-κB activa-
tion induced a dose-dependent decrease in the level of IL-22RA1 protein expression (A and B) and transcript expression (C and D).
Quantification of the IL-22RA1 protein expression is summarized in the lower panel for each inhibitor.
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detected in all cell lines and patient samples examined. The PCR
products were sequenced and confirmed to be full-length IL-10RB.
IL-22 Expression in MCL Cell Lines and Tumors
Using RT-PCR, we assessed if IL-22 is produced by MCL cells. As
shown in Figure 6A, no IL-22 signal was detectable in all three MCL
cell lines. In contrast, of the eight MCL tumor samples, amplifiable
IL-22 signal was detectable in five (63%) cases. Both benign periph-
eral blood B cells and HepG2 were negative (Figure 6B).
IL-22 Promotes Cell Growth and Activates STAT3 in
MCL Cells
To assess if the IL-22 signaling pathway is functionally intact and
if it exerts any significant biological effects in MCL cells, we added
rIL-22 to the cell culture of all three MCL cell lines (i.e., with 20 ng/ml
daily for up to 6 days). Daily cell counts were performed using Trypan
blue exclusion test. A significant increase in the number of viable
cells was observed on days 5 and 6 in all three cell lines (Figure 7,
A, D, and G ). To further support this finding, we performed MTS
assay under the same experimental condition; cells treated with rIL-
22 had a significant higher viable cell number than those without
rIL-22 on day 5 (Figure 7, B, E , and H ).
Because rIL-22 has been reported to activate various cell signaling
pathways, including that of STAT3, in a number of nonhematologic
cell lines [18,28,44,45], we investigated if rIL-22 also contributes to
STAT3 activation in MCL cells. We found that MCL cells treated
with increasing concentrations (from 5 to 80 ng/ml) of rIL-22 for
30 minutes showed a dose-dependent increase in the level of pSTAT3.
The expression levels of cyclin D1 and Bcl-2 were unchanged after
30 minutes of incubation with rIL-22.
IL-22RA1 Expression Can Be Partly Attributed to NF-κB
Activation in MCL
To investigate the mechanism underlying the aberrant expression
of IL-22RA1 in MCL, we analyzed the gene promoter of the IL-
22RA1 gene. Gene sequence analysis revealed that the IL-22RA1
gene promoter contains three consensus binding sequences for NF-
κB (illustrated in Table 2). Because NF-κB has been shown to be
biologically important for MCL [46,47], we hypothesized that NF-
κB may contribute to the aberrant expression of IL-22RA1 in this
cell type. Thus, we treated MCL cells lines with two highly specific in-
hibitors of NF-κB, including 6-amino-4-(phenoxyphenylethylamino)
quinazoline [48–52] and E -2-fluoro-4′-methoxystilbene [53]. As
shown in Figure 8, treatment of Mino cells with these two NF-κB
inhibitors for 24 hours induced a dose-dependent decrease in the pro-
tein expression of IL-22RA1. In this period, no evidence of cell death,
as assessed by Trypan blue exclusion test, was noted.
Discussion
Recent studies have provided insights into the biology of MCL. In ad-
dition to the overexpression of cyclin D1, a large number of biochem-
ical and genetic abnormalities have been identified in these neoplasms,
such as the constitutive activation of various signaling pathways includ-
ing those of STAT3 [17], Wnt [16], and NF-κB [46,47]. Our results
have provided evidence that IL-22RA1 is consistently expressed in
MCL cell lines and tumors. This conclusion is based on the results
of three different techniques, including RT-PCR, Western blots, and
confocal imaging. By contrast, IL-22RA1 is not detectable in benign
B cells. To our knowledge, this represents the first report in which the
aberrant expression of IL-22RA1 in a B-cell lymphoma is described.
We found that the IL-22 signaling is functional and biologically
significant in MCL cells. Specifically, the addition of rIL-22 activates
STAT3 and significantly promotes cell growth in all three MCL cell
lines. Our observations that rIL-22 promotes cell growth in MCL
correlates well with the previous reports that IL-22 promotes cell pro-
liferation and antiapoptotic effects in epithelial cell lines [39,54].
Our finding that rIL-22 activates STAT3 in MCL cells also correlates
well with the findings in various epithelial cell lines [41,45].
Regarding the source of IL-22, we found that most (63%) of our
cohort of MCL frozen tumors had detectable IL-22 expression,
whereas all three MCL cell lines did not produce detectable IL-22.
This finding indicates that IL-22 stimulation of MCL cells exists
in vivo in a subset of cases. Because IL-22 is normally produced by
T cells, endothelial cells, and histiocytes [23,24,26], it is highly pos-
sible that these same cell types may also release IL-22 in the tumor
microenvironment and promote the cell growth of MCL cells in vivo.
Moreover, IL-22 also has been shown to be present in the peripheral
blood of healthy people [37,55,56], and thus stimulation of MCL
cell can be maintained while they are in the circulation.
We also investigated the mechanism by which IL-22RA1 is aber-
rantly expressed in MCL cells. In this study, we found that IL-22RA1
expression can be partly attributed to NF-κB signaling because inhi-
bition of this pathway using two structurally different pharmacologic
agents resulted in a dramatic reduction of IL-22RA1 protein expres-
sion. The specificity of these two compounds has been previously
documented [48,53]. Of note, we previously investigated how IL-
22RA1 is aberrantly expressed in another type of malignant lymphoma,
namely ALK-positive anaplastic large cell lymphoma; we found that
IL-22RA expression in these cells was related to the oncogenic fusion
protein NPM-ALK that is characteristic of this type of lymphoma [42].
Taken together, the mechanisms leading to IL-22RA1 expression in
malignant lymphoid cells are likely to be variable and/or multifactorial.
In summary, we have demonstrated for the first time that IL-22RA1
is aberrantly expressed in a B-cell lymphoma. Our data also has pro-
vided evidence that IL-22 stimulation is biologically important, by
promoting the growth of MCL cells and activating the signaling of
STAT3, a protein known to be oncogenic when inappropriately acti-
vated. Targeting IL-22RA1 and/or blocking the endogenous produc-
tion of IL-22 may be a useful therapeutic strategy for MCL.
References
[1] Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, and
Vardiman JW (2008). Classification of Tumours of Haematopoietic and Lymphoid
Tissues, Fourth Edition. WHO Classification of Tumours, Volume 2. WHO, Geneva,
Switzerland. pp. 229–232.
[2] Ghielmini M and Zucca E (2009). How I treat mantle cell lymphoma. Blood
114, 1469–1476.
[3] Gill S and Ritchie D (2008). Therapeutic options in mantle cell lymphoma.
Leuk Lymphoma 49(3), 398–409.
[4] Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P,
Reiser M, Forstpointner R, Metzner B, Peter N, et al. (2009). Improvement of
overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 27(4),
511–518.
[5] Smith MR (2008). Mantle cell lymphoma: advances in biology and therapy.
Curr Opin Hematol 15(4), 415–421.
[6] Gladden AB and Diehl JA (2005). Location, location, location: the role of
cyclin D1 nuclear localization in cancer. J Cell Biochem 96(5), 906–913.
[7] Klier M, Anastasov N, Hermann A, Meindl T, Angermeier D, Raffeld M, Fend
F, and Quintanilla-Martinez L (2008). Specific lentiviral shRNA-mediated
knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on
Translational Oncology Vol. 4, No. 1, 2011 IL22 in Mantle Cell Lymphoma Gelebart et al. 17
cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 22(11),
2097–2105.
[8] Vater I, Wagner F, Kreuz M, Berger H, Martin-Subero JI, Pott C, Martinez-
Climent JA, Klapper W, Krause K, Dyer MJ, et al. (2009). GeneChip analyses
point to novel pathogenetic mechanisms in mantle cell lymphoma. Br J Haema-
tol 144(3), 317–331.
[9] Kawamata N, Ogawa S, Gueller S, Ross SH, Huynh T, Chen J, Chang A,
Nabavi-Nouis S, Megrabian N, Siebert R, et al. (2009). Identified hidden ge-
nomic changes in mantle cell lymphoma using high-resolution single nucleotide
polymorphism genomic array. Exp Hematol 37(8), 937–946.
[10] Schraders M, Jares P, Bea S, Schoenmakers EF, van Krieken JH, Campo E, and
Groenen PJ (2008). Integrated genomic and expression profiling in mantle cell
lymphoma: identification of gene-dosage regulated candidate genes. Br J Hae-
matol 143(2), 210–221.
[11] Cecconi D, Zamo A, Bianchi E, Parisi A, Barbi S, Milli A, Rinalducci S,
Rosenwald A, Hartmann E, Zolla L, et al. (2008). Signal transduction pathways
of mantle cell lymphoma: a phosphoproteome-based study. Proteomics 8(21),
4495–4506.
[12] Henrickson SE, Hartmann EM, Ott G, and Rosenwald A (2007). Gene expres-
sion profiling in malignant lymphomas. Adv Exp Med Biol 593, 134–146.
[13] Camps J, Salaverria I, Garcia MJ, Prat E, Bea S, Pole JC, Hernandez L, Del Rey
J, Cigudosa JC, Bernues M, et al. (2006). Genomic imbalances and patterns
of karyotypic variability in mantle-cell lymphoma cell lines. Leuk Res 30(8),
923–934.
[14] Rizzatti EG, Falcao RP, Panepucci RA, Proto-Siqueira R, Anselmo-Lima WT,
Okamoto OK, and Zago MA (2005). Gene expression profiling of mantle cell
lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT
and TGFbeta signalling pathways. Br J Haematol 130(4), 516–526.
[15] Ghobrial IM, McCormick DJ, Kaufmann SH, Leontovich AA, Loegering DA,
Dai NT, Krajnik KL, Stenson MJ, Melhem MF, Novak AJ, et al. (2005). Pro-
teomic analysis of mantle-cell lymphoma by protein microarray. Blood 105(9),
3722–3730.
[16] Gelebart P, Anand M, Armanious H, Peters AC, Dien Bard J, Amin HM, and
Lai R (2008). Constitutive activation of the Wnt canonical pathway in mantle
cell lymphoma. Blood 112(13), 5171–5179.
[17] Lai R, Rassidakis GZ, Medeiros LJ, Leventaki V, Keating M, and McDonnell TJ
(2003). Expression of STAT3 and its phosphorylated forms in mantle cell lym-
phoma cell lines and tumours. J Pathol 199(1), 84–89.
[18] Dumoutier L, Louahed J, and Renauld JC (2000). Cloning and characterization of
IL-10–related T cell–derived inducible factor (IL-TIF), a novel cytokine structur-
ally related to IL-10 and inducible by IL-9. J Immunol 164(4), 1814–1819.
[19] Dumoutier L, Van Roost E, Ameye G, Michaux L, and Renauld JC (2000). IL-
TIF/IL-22: genomic organization and mapping of the human and mouse genes.
Genes Immun 1(8), 488–494.
[20] Commins S, Steinke JW, and Borish L (2008). The extended IL-10 superfamily:
IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Im-
munol 121(5), 1108–1111.
[21] Chung Y, Yang X, Chang SH, Ma L, Tian Q, and Dong C (2006). Expression and
regulation of IL-22 in the IL-17-producing CD4+ T lymphocytes. Cell Res 16(11),
902–907.
[22] Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins
M, and Fouser LA (2006). Interleukin (IL)-22 and IL-17 are coexpressed by
Th17 cells and cooperatively enhance expression of antimicrobial peptides.
J Exp Med 203(10), 2271–2279.
[23] Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JK, Doherty JM,
Mills JC, and Colonna M (2009). A human natural killer cell subset provides an
innate source of IL-22 for mucosal immunity. Nature 457(7230), 722–725.
[24] Nograles KE, Zaba LC, Shemer A, Fuentes-Duculan J, Cardinale I, Kikuchi T,
Ramon M, Bergman R, Krueger JG, and Guttman-Yassky E (2009). IL-22-
producing “T22” T cells account for upregulated IL-22 in atopic dermatitis de-
spite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 123(6),
1244–1252, e1242.
[25] Ricciardi L, Minciullo PL, Saitta S, Trombetta D, Saija A, and Gangemi S (2009).
Increased serum levels of IL-22 in patients with nickel contact dermatitis. Contact
Dermatitis 60(1), 57–58.
[26] Vivier E, Spits H, and Cupedo T (2009). Interleukin-22–producing innate
immune cells: new players in mucosal immunity and tissue repair? Nat Rev
Immunol 9(4), 229–234.
[27] Trifari S, Kaplan CD, Tran EH, Crellin NK, and Spits H (2009). Identification
of a human helper T cell population that has abundant production of interleu-
kin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol
10(8), 864–871.
[28] Xie MH, Aggarwal S, Ho WH, Foster J, Zhang Z, Stinson J, Wood WI,
Goddard AD, and Gurney AL (2000). Interleukin (IL)-22, a novel human cy-
tokine that signals through the interferon receptor–related proteins CRF2-4 and
IL-22R. J Biol Chem 275(40), 31335–31339.
[29] Bleicher L, de Moura PR, Watanabe L, Colau D, Dumoutier L, Renauld JC,
and Polikarpov I (2008). Crystal structure of the IL-22/IL-22R1 complex
and its implications for the IL-22 signaling mechanism. FEBS Lett 582(20),
2985–2992.
[30] de Oliveira Neto M, Ferreira JR Jr, Colau D, Fischer H, Nascimento AS,
Craievich AF, Dumoutier L, Renauld JC, and Polikarpov I (2008). Interleukin-22
forms dimers that are recognized by two interleukin-22R1 receptor chains. Biophys J
94(5), 1754–1765.
[31] Jones BC, Logsdon NJ, and Walter MR (2008). Structure of IL-22 bound to its
high-affinity IL-22R1 chain. Structure 16(9), 1333–1344.
[32] Shioya M, Andoh A, Kakinoki S, Nishida A, and Fujiyama Y (2008). Interleu-
kin 22 receptor 1 expression in pancreas islets. Pancreas 36(2), 197–199.
[33] Ramanathan M Jr, Spannhake EW, and Lane AP (2007). Chronic rhinosinusitis
with nasal polyps is associated with decreased expression of mucosal interleukin 22
receptor. Laryngoscope 117(10), 1839–1843.
[34] Brand S, Dambacher J, Beigel F, Zitzmann K, Heeg MH, Weiss TS, Prufer T,
Olszak T, Steib CJ, Storr M, et al. (2007). IL-22–mediated liver cell regenera-
tion is abrogated by SOCS-1/3 overexpression in vitro. Am J Physiol Gastrointest
Liver Physiol 292(4), G1019–G1028.
[35] Nagalakshmi ML, Rascle A, Zurawski S, Menon S, and de Waal Malefyt R
(2004). Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial
cells. Int Immunopharmacol 4(5), 679–691.
[36] Lecart S, Morel F, Noraz N, Pene J, Garcia M, Boniface K, Lecron JC, and Yssel
H (2002). IL-22, in contrast to IL-10, does not induce Ig production, due to
absence of a functional IL-22 receptor on activated human B cells. Int Immunol
14(11), 1351–1356.
[37] Ratsep R, Kingo K, Karelson M, Reimann E, Raud K, Silm H, Vasar E, and
Koks S (2008). Gene expression study of IL10 family genes in vitiligo skin
biopsies, peripheral blood mononuclear cells and sera. Br J Dermatol 159(6),
1275–1281.
[38] Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, Warntjen M, Lehr
HA, Hirth S, Weigmann B, Wirtz S, et al. (2009). STAT3 links IL-22 signal-
ing in intestinal epithelial cells to mucosal wound healing. J Exp Med 206(7),
1465–1472.
[39] Zhang W, Chen Y, Wei H, Zheng C, Sun R, Zhang J, and Tian Z (2008).
Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of
interleukin-22-small interfering RNA on human lung cancer xenografts. Clin
Cancer Res 14(20), 6432–6439.
[40] Ziesche E, Bachmann M, Kleinert H, Pfeilschifter J, and Muhl H (2007). The
interleukin-22/STAT3 pathway potentiates expression of inducible nitric-oxide
synthase in human colon carcinoma cells. J Biol Chem 282(22), 16006–16015.
[41] Weber GF, Gaertner FC, Erl W, Janssen KP, Blechert B, Holzmann B,
Weighardt H, and Essler M (2006). IL-22-mediated tumor growth reduction
correlates with inhibition of ERK1/2 and AKT phosphorylation and induction
of cell cycle arrest in the G2-M phase. J Immunol 177(11), 8266–8272.
[42] Bard JD, Gelebart P, Anand M, Amin HM, and Lai R (2008). Aberrant expres-
sion of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumor-
igenecity in ALK+ anaplastic large cell lymphoma. Leukemia 22, 1595–1603.
[43] Amin HM, McDonnell TJ, Medeiros LJ, Rassidakis GZ, Leventaki V,
O’Connor SL, Keating MJ, and Lai R (2003). Characterization of 4 mantle cell
lymphoma cell lines. Arch Pathol Lab Med 127(4), 424–431.
[44] Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E, Dickensheets H,
Donnelly RP, and Pestka S (2001). Identification of the functional interleukin-22
(IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta) is a common chain of
both the IL-10 and IL-22 (IL-10–related T cell–derived inducible factor, IL-TIF)
receptor complexes. J Biol Chem 276(4), 2725–2732.
[45] Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, and
Renauld JC (2002). Interleukin-22 (IL-22) activates the JAK/STAT, ERK,
JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that
are shared with and distinct from IL-10. J Biol Chem 277(37), 33676–33682.
[46] Shishodia S, Amin HM, Lai R, and Aggarwal BB (2005). Curcumin (diferuloyl-
methane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, sup-
presses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem
Pharmacol 70(5), 700–713.
18 IL22 in Mantle Cell Lymphoma Gelebart et al. Translational Oncology Vol. 4, No. 1, 2011
[47] Roue G, Perez-Galan P, Lopez-Guerra M, Villamor N, Campo E, and Colomer
D (2007). Selective inhibition of IkappaB kinase sensitizes mantle cell lym-
phoma B cells to TRAIL by decreasing cellular FLIP level. J Immunol 178(3),
1923–1930.
[48] Choi S, Kim JH, Roh EJ, Ko MJ, Jung JE, and Kim HJ (2006). Nuclear factor-
kappaB activated by capacitative Ca2+ entry enhances muscarinic receptor–
mediated soluble amyloid precursor protein (sAPPalpha) release in SH-SY5Y
cells. J Biol Chem 281(18), 12722–12728.
[49] Curry CL, Reed LL, Broude E, Golde TE, Miele L, and Foreman KE (2007).
Notch inhibition in Kaposi’s sarcoma tumor cells leads to mitotic catastrophe
through nuclear factor-kappaB signaling. Mol Cancer Ther 6(7), 1983–1992.
[50] Tobe M, Isobe Y, Tomizawa H, Nagasaki T, Takahashi H, and Hayashi H
(2003). A novel structural class of potent inhibitors of NF-kappa B activation:
structure-activity relationships and biological effects of 6-aminoquinazoline de-
rivatives. Bioorg Med Chem 11(18), 3869–3878.
[51] Yang RH, Strong JA, and Zhang JM (2009). NF-kappaB mediated enhance-
ment of potassium currents by the chemokine CXCL1/growth related oncogene
in small diameter rat sensory neurons. Mol Pain 5, 26.
[52] Armstrong SJ, Wiberg M, Terenghi G, and Kingham PJ (2008). Laminin acti-
vates NF-kappaB in Schwann cells to enhance neurite outgrowth. Neurosci Lett
439(1), 42–46.
[53] Heynekamp JJ, Weber WM, Hunsaker LA, Gonzales AM, Orlando RA, Deck
LM, and Jagt DL (2006). Substituted trans-stilbenes, including analogues of the
natural product resveratrol, inhibit the human tumor necrosis factor alpha–
induced activation of transcription factor nuclear factor kappaB. J Med Chem
49(24), 7182–7189.
[54] Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diepolder H,
Marquardt A, Jagla W, Popp A, et al. (2006). IL-22 is increased in active Crohn’s
disease and promotes proinflammatory gene expression and intestinal epithelial
cell migration. Am J Physiol Gastrointest Liver Physiol 290(4), G827–G838.
[55] Pan HF, Zhao XF, Yuan H, Zhang WH, Li XP, Wang GH, Wu GC, Tang XW,
Li WX, Li LH, et al. (2009). Decreased serum IL-22 levels in patients with
systemic lupus erythematosus. Clin Chim Acta 401(1-2), 179–180.
[56] Cheng F, Guo Z, Xu H, Yan D, and Li Q (2009). Decreased plasma IL22 levels,
but not increased IL17 and IL23 levels, correlate with disease activity in patients
with systemic lupus erythematosus. Ann Rheum Dis 68(4), 604–606.
Translational Oncology Vol. 4, No. 1, 2011 IL22 in Mantle Cell Lymphoma Gelebart et al. 19
